# Top 5 interesting findings — SGLT2_inhibitors

**Snapshot:** 2026-05-27T06-20-54Z
**Source:** Researka DB Tier-2 search (`POST /api/v1/tier2/facts/search`, filter topic=SGLT2_inhibitors) — LLM-extracted, no Tier-1 canonical facts loaded for this topic yet; findings may be off-target (e.g. chemistry papers using the molecule name) until canonical curation.
**Facts inspected:** 10
**Ranking:** validation * magnitude * precision * recency (deterministic, no LLM), then one coherent broad theme is selected by aggregate score. Same-paper + same-sub_topic findings are collapsed; extra biomarkers from the same trial appear as supporting numerics under the headline.

**Selected theme:** `intervention_signal` (facet counts: clinical_outcome=5)

**Sub-topic lanes detected:** facts grouped by `sub_topic` below — read each lane independently.

---

### Lane — `effect_size`


## #1 — score 100 · effect_size

**Finding:** reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91)

- **Value:** 0.83HR
- **Population:** patients with type 2 diabetes mellitus
- **Intervention:** SGLT2 inhibitors
- **Alpha cues:** translation_context, functional_endpoint
- **Source:** *SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies* — Pharmacological Research (2021)
  · DOI: `10.1016/j.phrs.2021.105836`
- **Validator:** researka-tier2
- **Same-trial supporting numerics:** 0.89HR (reduced risk of stroke with SGLT2 inhibitors compared to DPP)

- **Why it matters:** SGLT2 inhibitors can reduce stroke risk in diabetic patients, potentially preventing disability and lowering healthcare burdens.
- **Caution:** The hazard ratio is derived from observational data, which may be confounded by unmeasured variables or treatment biases.
- **Next question:** Do these stroke benefits extend to non-diabetic populations or vary with different SGLT2 inhibitor types?

---

## #2 — score 68 · effect_size

**Finding:** SGLT2 inhibitors decreased the risk of serious heart failure events by 25-40%

- **Value:** 25.0%
- **Population:** >40 000 patients across five large-scale trials
- **Intervention:** sodium-glucose cotransporter 2 (SGLT2) inhibitors
- **Alpha cues:** baseline
- **Source:** *Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors* — European Journal of Heart Failure (2020)
  · DOI: `10.1002/ejhf.1732`
- **Validator:** researka-tier2

- **Why it matters:** A 25-40% reduction in serious heart failure events can significantly decrease hospitalizations and improve quality of life for high-risk patients.
- **Caution:** The effect range spans multiple trials with heterogeneous designs and dosing, limiting precise generalizability.
- **Next question:** What are the long-term cardiovascular and renal outcomes of SGLT2 inhibitors for heart failure prevention beyond five years?

---

## #3 — score 60 · effect_size

**Finding:** those with heart failure treated with SGLT2 inhibitors had a 20% relative risk reduction in cardiovascular deaths and heart failure hospitalizations (risk ratio, 0.78; P<0.001).

- **Value:** 0.78RR
- **Population:** patients without diabetes mellitus with heart failure
- **Intervention:** SGLT2 inhibitors
- **Alpha cues:** baseline
- **Source:** *Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized‐Controlled Trials* — Journal of the American Heart Association (2021)
  · DOI: `10.1161/jaha.120.019463`
- **Validator:** researka-tier2

- **Why it matters:** SGLT2 inhibitors offer a 20% risk reduction in cardiovascular deaths and hospitalizations for heart failure patients without diabetes, broadening treatment options.
- **Caution:** This subgroup analysis may lack power for definitive conclusions and could be influenced by trial-specific inclusion criteria.
- **Next question:** How do SGLT2 inhibitors compare to established heart failure drugs like beta-blockers in terms of cost-effectiveness and adherence?

---

## #4 — score 60 · effect_size

**Finding:** lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia

- **Value:** 0.6%
- **Population:** patients with type 2 diabetes
- **Intervention:** SGLT2 inhibitors
- **Alpha cues:** baseline
- **Source:** *SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?* — Diseases (2020)
  · DOI: `10.3390/diseases8020014`
- **Validator:** researka-tier2

- **Why it matters:** Lowering HbA1c by 0.6-0.8% without increased hypoglycemia allows for safer glycemic control, reducing diabetes-related complications.
- **Caution:** The average HbA1c reduction does not account for individual variability due to factors like renal function or concurrent therapies.
- **Next question:** What is the impact of SGLT2 inhibitors on microvascular outcomes, such as diabetic retinopathy or nephropathy progression?

---

### Lane — `adverse`


## #5 — score 60 · adverse

**Finding:** hypotension occurred more often with non-selective SGLT2 inhibitors (odds ratio [OR], 1.87; 95% CI, 1.20-2.92)

- **Value:** 1.87OR
- **Population:** patients with T2DM
- **Intervention:** non-selective SGLT2 inhibitors
- **Alpha cues:** baseline
- **Source:** *Effect of pharmacological selectivity of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes: a meta-analysis* — Scientific Reports (2024)
  · DOI: `10.1038/s41598-024-52331-w`
- **Validator:** researka-tier2

- **Why it matters:** Increased hypotension risk with non-selective SGLT2 inhibitors guides clinicians to monitor blood pressure and adjust therapy in vulnerable patients.
- **Caution:** The odds ratio is based on comparative studies where dose adjustments and patient comorbidities may affect the observed risk.
- **Next question:** Do selective SGLT2 inhibitors provide similar glycemic and cardiovascular benefits with a lower incidence of hypotension?

---
